Business
genedrive plc awarded Innovate UK grant
genedrive plc awarded Innovate UK grant.
About this update from Genedrive Plc
[{"type":"text","content":"\n \nRNS Number : 0378X Genedrive PLC 21 November 2017 \n\nFor release: 21 November 2017\n \n \ngenedrive plc (\"genedrive\" or the \"Company\")\n \ngenedrive plc awarded £600,000 Innovate UK grant\n \nAward to support the development of a centrifuge-free plasma separation consumable for its Genedrive® HCV assay\n \ngenedrive plc, the near patient molecular diagnostics company, today announces it has now been formally awarded an Innovate UK grant for the development of a disposable centrifuge-free plasma separation consumable device. In its preliminary results issued in October, genedrive confirmed it had been conditionally offered this grant. The device is planned to support the future use of genedrive's HCV ID Kit closer to a point of care setting. genedrive plc and its collaborators, NHS Tayside and the Univeristy of Dundee, will receive circa £600,000 of which genedrive will account for its £484,000 share of the funding as income, matched to costs incurred over the periods to 30 June 2018 and 2019.\n \nDavid Budd, Chief Executive Officer of genedrive plc said: \"This has the opportunity to be a very novel and impactful project and we are delighted that Innovate UK has chosen to support us. This device will aim to improve the applicability of the Genedrive® HCV assay for closer to patient settings and would be a significant step forward in positioning the test for true decentralised diagnostics. Further, the device is anticipated to be independent from the Genedrive® platform, opening the opportunity for other diagnostic instruments that need plasma as a starting point for blood borne viral testing.\"\n \nGenedrive® HCV ID Kit is performed on the Company's Genedrive® portable molecular diagnostics platform, designed for use at the point of need. The assay uses only a small amount of human plasma (25ul), eliminating the need for a separate RNA viral extraction process, and yields results within 90 minutes. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and Asia Pacific regions.\n \n \n- Ends -\n \nFor further details please contact:\ngenedrive plc\nDavid Budd: CEO &...